Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

NCT05532059 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cholangiocarcinoma

Interventions

DRUG: Lenvatinib, tislelizumab, gemcitabine and cisplatin
DRUG: gemcitabine and cisplatin

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University